Antimicrobial Resistance: Why Stewardship Must Become Non-Negotiable

By Emmanuel Kwabena Owusu KNUST, 3rd Year Student, Department of Environmental Science

INTRODUCTION

Antimicrobial resistance is one of the most serious public health threats of our time. Every year, it is estimated to kill about 700,000 people worldwide, and projections suggest that number could rise to 10 million annual deaths by 2050 if current trends continue (O’Neill, 2014). This crisis has been fueled by decades of antibiotic overuse in both healthcare and agriculture, where drugs meant to save lives are often used carelessly. If this pattern continues, modern medicine risks sliding back toward a pre-antibiotic era in which ordinary infections become deadly once again.

The scale of the problem is already alarming. The World Health Organization’s 2019 priority pathogen list highlights twelve bacteria that are resistant to multiple drug classes, including critical threats such as carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa (WHO, 2020). The consequences are not theoretical. India records tens of thousands of neonatal deaths annually from resistant infections, while methicillin-resistant Staphylococcus aureus costs the United States billions of dollars in excess healthcare spending each year (Thabit et al., 2019). These figures show that antimicrobial resistance is not a future concern; it is an ongoing crisis affecting patient survival, hospital resources, and public health systems across the world.

One major driver of resistance is inappropriate clinical prescribing. Hospitals are among the main settings where resistance develops and spreads. Research shows that a large proportion of antibiotic prescriptions in acute-care settings are unnecessary or inappropriate, often given for viral illnesses where antibiotics offer no benefit (Stewardson et al., 2019). This kind of misuse creates strong selection pressure, allowing resistant bacteria to survive and multiply. Encouragingly, studies have shown that stewardship interventions can reduce unnecessary broad-spectrum antibiotic use without harming patient outcomes. This means that better prescribing practices can protect both current patients and future generations.

Agricultural antibiotic use is another major contributor. In many countries, antibiotics are routinely used in livestock production not only to treat disease but also to promote growth in crowded farming conditions. In the United States, livestock account for a large share of antibiotic sales for food-producing animals (FDA, 2023). Resistant bacteria can spread from animals to humans through food, water, and the environment, making resistance a truly transnational problem. Because of this, the solution cannot rest on hospitals alone. It requires coordinated international regulation that limits non-therapeutic antibiotic use in agriculture.

Some critics argue that stricter antibiotic controls could deny patients life-saving treatment. That concern misunderstands the purpose of stewardship. Stewardship does not ban antibiotics; it ensures they are used properly. A patient with a confirmed bacterial infection should receive antibiotics, but a patient with a viral infection should not be exposed to unnecessary drugs. In this way, stewardship preserves antibiotic effectiveness while reducing resistance pressure.

Antimicrobial resistance is not inevitable. It is a human-made crisis driven by misuse, weak regulation, and inconsistent enforcement. Healthcare institutions must adopt mandatory stewardship programs, and governments must support international policies that reduce unnecessary antibiotic use in both clinical and agricultural settings. Without such action, antibiotics may lose their power within this generation. The choice is clear: responsible stewardship now, or dangerous resistance later.

References

Davey, P., Marwick, C. A., Scott, C. L., Charani, E., McNeil, K., Brown, E., … & Michie, S. (2017). Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database of Systematic Reviews, 2, CD003543.

FDA. (2023). Antimicrobials sold or distributed for use in food-producing animals. U.S. Food and Drug Administration.

O’Neill, J. (2014). Antimicrobial resistance: Tackling a crisis for the health and wealth of nations. The Review on Antimicrobial Resistance.

Stewardson, A. J., Schrenzel, J., Pittet, D., & Bellomo, R. (2019). Quantifying the impacts of antibiotics for transparency and stewardship. Nature Reviews Microbiology, 17(10), 615–632.

Thabit, A. K., Haroon, F. F., Tarrand, J. J., & Lumbard, A. G. (2019). Impact of antimicrobial stewardship on the prevalence of multidrug-resistant organisms among hospitalized patients. American Journal of Infection Control, 47(1), 81–87.

van Duin, D., & Paterson, D. L. (2016). Multidrug-resistant bacteria in the community: Trends and lessons learned. Infectious Disease Clinics of North America, 30(2), 377–390.

WHO. (2020). Antimicrobial resistance: Global report on surveillance. World Health Organization.